THE PLASMA CONCENTRATION OF ACEBROPHYLLINE MAY BE INCREASED BY CONCURRENT ADMINISTRATION OF ERYTHROMYCIN, CEPHALEXIN, OXYTETRACYLINE, OLIGOMYCIN, LINCOMYCIN, CIMETIDINE, CLINDAMYCIN, AILOPURINOI, QUINOLONES, ANTICOAGULANTS, ETC. IF CONCOMITANT USE IS ESSENTIAL, THE DOSE OF ACEBROPHYLLINE SHOULD BE REDUCED. THE CONCOMITANT BSE OF ACEBROPHYLLINE AND FUROSEMIDE CAN POTENTIATE DIURESIS, WHILE CONCOMITANT USE OF ACEBROPHYLLINE WITH RESERPINE CAN CAUSE TACHYCARDIA. ACEBROPHYLLINE PLASMA CONCENTRATION MAY BE DECREASED IN PATIENTS BY COADMINISTRATION WITH DRUGS LIKE PHENYTOIN AND BARBITURATES AND IN PATIENTS WHO SMOKE. IT IS ADVISABLE NOT TO USE ACEBROPHYLLINE WITH ANY OTHER THEOPHYLLINE DERIVATIVE,AMBROXOL DERIVATIVE OR CENTRAL NERVOUS SYSTEM STIMULANTS. CAUTION IS ADVISED WHEN ACEBROPHYLLINE IS USED WITH EPHEDRINE, SYMPATHOMIMETICS AND ANY OTHER BRONCHODILATOR.